72 studies found for:    INFLAMMATORY BOWEL DISEASE 3
Show Display Options
Rank Status Study
1 Completed A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.
Conditions: Crohn's Disease;   Inflammatory Bowel Disease
Intervention: Drug: Probiotic - VSL#3
2 Completed Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
Conditions: Crohn's Disease (CD);   Ulcerative Colitis (UC)
Intervention: Dietary Supplement: Vitamin D3
3 Recruiting The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease
Conditions: Crohn Disease;   Ulcerative Colitis
Intervention: Dietary Supplement: VSL#3
4 Recruiting Weekly Vitamin D in Pediatric IBD
Conditions: Inflammatory Bowel Diseases;   Skin Pigmentation
Intervention: Dietary Supplement: Vitamin D3 (cholecalciferol)
5 Recruiting The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vitamin D;   Drug: Placebo
6 Enrolling by invitation A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Conditions: Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
Interventions: Drug: Placebo;   Drug: Ustekinumab
7 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   IBD;   Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo;   Drug: Group 2 ustekinumab 130 mg
8 Completed A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Conditions: Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
9 Active, not recruiting Oral OKT3 for the Treatment of Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Oral OKT3
10 Recruiting Gastrointestinal Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit
Condition: Ulcerative Colitis
Intervention: Device: Motilis-3D-transit
11 Recruiting Gastrointestinal Transit Times and Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit
Condition: Ulcerative Colitis
Intervention: Device: Motilis-3D transit
12 Recruiting A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: VSL#3
13 Completed Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Dietary Supplement: VSL#3;   Dietary Supplement: Placebo
14 Recruiting The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease
Condition: Crohn's Disease
Intervention: Dietary Supplement: VSL#3
15 Completed Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
Condition: Crohn's Disease
Intervention: Drug: Infliximab
16 Completed Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Dietary Supplement: VSL#3;   Dietary Supplement: Placebo
17 Unknown  VSL#3 Treatment in Children With Crohn's Disease
Condition: Crohn's Disease
Interventions: Dietary Supplement: VSL#3®;   Dietary Supplement: Placebo
18 Completed VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: VSL#3;   Other: Placebo
19 Completed Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Condition: Crohn's Disease
Interventions: Drug: Semapimod;   Drug: Placebo
20 Completed 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
Condition: Crohn´s Disease
Intervention: Drug: budesonide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years